© 2005 Oxford University Press
ARTICLE |
Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment
Affiliation of authors: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Correspondence to: Mirjana Urosevic, MD, Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland (e-mail: Mirjana.Urosevic{at}usz.ch) or Reinhard Dummer, MD, Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland (e-mail: Reinhard.Dummer{at}usz.ch).
Background: Imiquimod, an immune response modifier that is used topically to treat different types of skin cancer, induces the production of proinflammatory cytokines that stimulate an antitumor immune response. We assessed characteristics of the imiquimod-induced immune activation in epithelial and lymphoproliferative neoplasias of human skin. We focused on plasmacytoid predendritic cells (PDCs), the primary producer of interferon 
(IFN-) after imiquimod activation in vitro. Methods: We used Affymetrix oligonucleotide arrays to compare gene expression profiles from tumors from 16 patients, 10 with superficial basal cell carcinomas (sBCCs), five with cutaneous T-cell lymphomas (CTCLs), and one with Bowen's disease, before and after topical imiquimod treatment. We used quantitative immunohistochemistry with PDC-specific antibodies against BDCA-2 and CD123 to characterize the PDC population before and after imiquimod treatment in these specimens. Activation status of PDCs from four sBCC patients was assessed by intracellular IFN- staining and flow cytometry. Results: Expression of various IFN-–inducible genes (e.g., CIG5, G1P2, OASL, IFIT1, STAT1, IFI35, OAS1, ISG20, MxA, and IRF7), the so-called IFN- signature, was increased similarly in both sBCC and CTCL lesions after imiquimod treatment. PDCs were recruited and activated in both lesion types, and they produced IFN- after imiquimod treatment in vivo (mean percentage of PDCs producing IFN- = 14.5%, 95% confidence interval [CI] = 4.9% to 24%; range = 3.3%–27%, n = 4 lesions). Imiquimod induced similar immune activation patterns in all three diseases, and these patterns were associated with the number of PDCs recruited to the treatment site. Two imiquimod-treated sBCC patients who did not mount an inflammatory response to imiquimod and whose lesions lacked the IFN- signature after treatment had fewer PDCs in treated lesions compared with other treated patients with such a response. Conclusions: Imiquimod induces immune activation patterns that relate to the number of the PDCs recruited to the treatment site, thus supporting the role of PDC in responsiveness to imiquimod in humans.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. L. J. M. Smits, P. Ponsaerts, Z. N. Berneman, and V. F. I. Van Tendeloo The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy Oncologist, August 1, 2008; 13(8): 859 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Adams, D. W. O'Neill, D. Nonaka, E. Hardin, L. Chiriboga, K. Siu, C. M. Cruz, A. Angiulli, F. Angiulli, E. Ritter, et al. Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant J. Immunol., July 1, 2008; 181(1): 776 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Astry, W. Birmachu, L. I. Harrison, and T.-C. Meng Cutaneous Pharmacodynamics of a Toll-Like Receptor 7 Agonist, 852A, in Humans J. Clin. Pharmacol., June 1, 2008; 48(6): 755 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dummer, A. Hauschild, J. C. Becker, J.-J. Grob, D. Schadendorf, V. Tebbs, J. Skalsky, K. C. Kaehler, S. Moosbauer, R. Clark, et al. An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma Clin. Cancer Res., February 1, 2008; 14(3): 856 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Whitmore, A. Iparraguirre, L. Kubelka, W. Weninger, T. Hai, and B. R. G. Williams Negative Regulation of TLR-Signaling Pathways by Activating Transcription Factor-3 J. Immunol., September 15, 2007; 179(6): 3622 - 3630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Stary, C. Bangert, M. Tauber, R. Strohal, T. Kopp, and G. Stingl Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells J. Exp. Med., June 11, 2007; 204(6): 1441 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Audige, M. Urosevic, E. Schlaepfer, R. Walker, D. Powell, S. Hallenberger, H. Joller, H.-U. Simon, R. Dummer, and R. F. Speck Anti-HIV State but Not Apoptosis Depends on IFN Signature in CD4+ T Cells J. Immunol., November 1, 2006; 177(9): 6227 - 6237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Inglefield, C. J. Larson, S. J. Gibson, H. Lebrec, and R. L. Miller Apoptotic Responses in Squamous Carcinoma and Epithelial Cells to Small-Molecule Toll-like Receptor Agonists Evaluated with Automated Cytometry J Biomol Screen, September 1, 2006; 11(6): 575 - 585. [Abstract] [PDF]
|
|